合并镰状细胞病对急性缺血性卒中溶栓治疗安全性与结局无影响:来自Get With The Guidelines-Stroke的发现
该研究基于美国Get With The Guidelines-Stroke注册数据库,将832例合并镰状细胞病(SCD)的卒中患者与3328例无SCD对照进行匹配,比较溶栓使用率、并发症及出院结局。结果显示两组溶栓率(8.2% vs 9.4%)及症状性颅内出血率(4.9% vs 3.2%,P=0.4502)无差异,预设结局指标亦无差异。结论提示合并SCD不影响溶栓安全性与结局,符合条件的SCD成人急性缺血性卒中患者应接受溶栓治疗。
要点
- 合并SCD的急性缺血性卒中患者溶栓率与无SCD者无显著差异。
- SCD患者症状性颅内出血率与对照相比无统计学差异(P=0.4502)。
- 符合条件的SCD成人急性缺血性卒中患者应接受溶栓治疗。
核心结论
- 合并镰状细胞病对急性缺血性卒中溶栓治疗的安全性与结局无显著影响。
- 尽管样本量相对较小,数据提示符合条件的SCD成人急性缺血性卒中患者应接受溶栓治疗。
研究设计与样本
- 研究基于美国心脏协会/美国卒中协会Get With The Guidelines-Stroke注册数据库。
- 将832例合并SCD的卒中患者与3328例无SCD对照进行匹配,两组入院NIHSS评分或血压无差异。
- 使用广义估计方程的多变量逻辑回归模型评估结局。
主要发现
- 溶栓治疗比例:SCD组8.2%,非SCD组9.4%,两组无差异。
- 症状性颅内出血:SCD组4.9%,非SCD组3.2%,P=0.4502。
- 预设的结局指标在SCD组与对照组之间均无差异。
关键数值与推荐
- SCD并非tPA的已知禁忌证,但NIH国家心肺血液研究所推荐对SCD卒中行急性交换输血而非tPA。
- 本研究表明合并SCD不影响溶栓安全性与结局,支持对符合条件的SCD成人急性缺血性卒中患者使用溶栓治疗。
临床怎么用
- 对于合并SCD的急性缺血性卒中成人患者,若符合溶栓条件,应接受溶栓治疗。
- 需进一步研究追踪颅内出血率并提供其他SCD相关治疗(如输血)的信息。
局限性
- 样本量相对较小。
- 需要更多研究追踪颅内出血率并提供其他SCD相关治疗信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The recommended treatment for ischemic stroke is tPA (tissue-type plasminogen activator). Although sickle cell disease (SCD) represents no known contraindication to tPA, National Heart Lung and Blood Institute of the National Institutes of Health recommended acute exchange transfusion for stroke in SCD, not tPA. Data on safety and outcomes of tPA in patients are needed to guide tPA use in SCD. METHODS: We matched patients from the American Heart Association and American Stroke Association Get With The Guidelines-Stroke registry with SCD to patients without SCD and compared usage, complications, and discharge outcomes after tPA. Multivariable logistic regression models using generalized estimating equations were used to assess outcomes. RESULTS: From 2 016 652 stroke patients admitted to Get With The Guidelines-Stroke sites in the United States, 832 SCD and 3328 non-SCD controls with no differences in admission National Institutes of Health Stroke Scale or blood pressure were identified. Neither the fraction receiving thrombolytic therapy (8.2% for SCD versus 9.4% non-SCD) nor symptomatic intracranial hemorrhage (4.9% of SCD versus 3.2% non-SCD; P=0.4502) was different. There was no difference in a prespecified set of outcome measures for those with SCD compared with controls. CONCLUSIONS: Coexistent SCD had no significant impact on the safety or outcome of thrombolytic therapy in acute ischemic stroke. Although the sample size is relatively small, these data suggest that adults with SCD and acute ischemic stroke should be treated with thrombolysis, if they otherwise qualify. Addition studies, however, should track the intracranial hemorrhage rate and provide information on other SCD-related care such as transfusion.
引用
- Adams RJ, Cox M, Ozark SD, et al. Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke. Stroke. 2017. PMID: 28183857. doi:10.1161/STROKEAHA.116.015412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。